A Phase 2 interventional study of nemolizumab in Systemic Sclerosis, sponsored by Maruho Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Maruho Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Scleroderma, Systemic with a site in Japan — 4 open to participants now, 6 under way, 6 of them phase 3. Scleroderma, Systemic · Japan.
Among the 18 studies in Scleroderma, Systemic with a site in Japan, this one is the 18th largest by enrollment, is one of 4 that started in 2022, is one of 6 in phase 2, and was the 11th registered.
613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.
Browse Scleroderma, Systemic studies →4 of the 18 studies in Scleroderma, Systemic with a site in Japan are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Japan, United States, Argentina and 32 more countries
Ages 5–80
Boehringer Ingelheim · Sites in Japan, United States, Argentina and 42 more countries
Ages 18+
GlaxoSmithKline · Sites in Japan, United States, Argentina and 15 more countries
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in Japan, United States, Belgium and 7 more countries
Ages 16+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 20 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 11
First in 2006; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 37 across 449 interventional studies indexed under Scleroderma, Systemic.
Median enrollment 111 across the 18 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 18 have an industry lead sponsor. The 10 most frequent:
Maruho Co., Ltd. is the lead sponsor of 27 studies on the registry; none are open to participants now.
Maruho Co., Ltd. has 1 study filed under Scleroderma, Systemic — fewer than ten, so there is no comparison to draw.
1 of the studies in Scleroderma, Systemic with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Scleroderma, Systemic with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of nemolizumab in systemic sclerosis patients. To evaluate also the safety and pharmacokinetics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: nemolizumab
nemolizumab will be administered subcutaneous injection
Change From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 24
Compare pre- and post-treatment total mRSS at Week 24. The investigator assessed the degree of skin thickening for each of 17 sites (fingers of both hands, dorsum of both hands, both forearms, both upper arms, face, anterior chest, abdomen, both thighs, both lower legs, and dorsum of both feet) with a 4-point scale from 0 to 3; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness. The total mRSS is the sum of the mRSS of 17 site
Time frame: Baseline and week 24
Change From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 52
Compare pre- and post-treatment total mRSS at Week 52. The investigator assessed the degree of skin thickening for each of 17 sites (fingers of both hands, dorsum of both hands, both forearms, both upper arms, face, anterior chest, abdomen, both thighs, both lower legs, and dorsum of both feet) with a 4-point scale from 0 to 3; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness. The total mRSS is the sum of the mRSS of 17 site
Time frame: From baseline up to Week 52
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24
Compare pre- and post-treatment HAQ-DI at Week 24. The HAQ is a questionnaire that patients with chronic diseases answer themselves to assess physical function related to activities of daily living. The questionnaire consists of 20 questions divided into eight categories (dressing and grooming, standing, eating, walking, hygiene, movement, grip strength, and others), which are rated on a four-point scale from 0 to 3. 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. The highest value in each category is the index for that category, and the average of these is the HAQ-DI. The higher the HAQ-DI, the greater the degree of functional impairment.
Time frame: From baseline up to Week 24
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 52
Compare pre- and post-treatment HAQ-DI at Week 52. The HAQ is a questionnaire that patients with chronic diseases answer themselves to assess physical function related to activities of daily living. The questionnaire consists of 20 questions divided into eight categories (dressing and grooming, standing, eating, walking, hygiene, movement, grip strength, and others), which are rated on a four-point scale from 0 to 3. 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. The highest value in each category is the index for that category, and the average of these is the HAQ-DI. The higher the HAQ-DI, the greater the degree of functional impairment.
Time frame: From baseline up to Week 52
Change From Baseline in Percent Forced Vital Capacity (% FVC) at Week 24
Compare pre- and post-treatment %FVC at Week 24. %FVC is the ratio of the actual measured FVC to the predicted FVC (predicted based on gender, age, and height).
Time frame: From baseline up to Week 24
Change From Baseline in Percent Forced Vital Capacity (% FVC) at Week 52
Compare pre- and post-treatment %FVC at Week 52. %FVC is the ratio of the actual measured FVC to the predicted FVC (predicted based on gender, age, and height).
Time frame: From baseline up to Week 52
Change From Baseline in Percent Diffusing Capacity of Lung for Carbon Monoxide (%DLco) at Week 24
Compare pre- and post-treatment %DLco at Week 24. Pulmonary diffusion capacity refers to the ability to supply gases such as oxygen from alveoli to the alveolar capillaries. DLco is measured for carbon monoxide (CO) and is expressed as the volume (mL) of CO that transfers from alveolar air to the blood per minute per 1mmHg of alveolar partial pressure. %DLco is the ratio of the actual measured DLco to the predicted DLco (predicated based on age, sex, and height)
Time frame: From baseline up to Week 24
Change From Baseline in Percent Diffusing Capacity of Lung for Carbon Monoxide (%DLco) at Week 52
Compare pre- and post-treatment %DLco at Week 52. Pulmonary diffusion capacity refers to the ability to supply gases such as oxygen from alveoli to the alveolar capillaries. DLco is measured for carbon monoxide (CO) and is expressed as the volume (mL) of CO that transfers from alveolar air to the blood per minute per 1mmHg of alveolar partial pressure. %DLco is the ratio of the actual measured DLco to the predicted DLco (predicated based on age, sex, and height)
Time frame: From baseline up to Week 52
Change From Baseline in Physician's Global Assessment at Week 24
Compare pre- and post-treatment physician's global assessment at Week 24. Physician's global assessment is a visual analogue scale in which the attending physician assess the condition of systemic sclerosis based on severity, damage, and overall disease status. 0 is the best condition and 10 is the worst condition.
Time frame: From baseline up to Week 24
Change From Baseline in Physician's Global Assessment at Week 52
Compare pre- and post-treatment physician's global assessment at Week 52. Physician's global assessment is a visual analogue scale in which the attending physician assess the condition of systemic sclerosis based on severity, damage, and overall disease status. 0 is the best condition and 10 is the worst condition.
Time frame: From baseline up to Week 52
Change From Baseline in Patient's Global Assessment at Week 24
Compare pre- and post-treatment patient's global assessment at Week 24. Patient's Global Assessment is a visual analogue scale in which patients rate their systemic sclerosis condition, with 0 being the best and 10 being the worst.
Time frame: From baseline up to Week 24
Change From Baseline in Patient's Global Assessment at Week 52
Compare pre- and post-treatment patient's global assessment at Week 52. Patient's Global Assessment is a visual analogue scale in which patients rate their systemic sclerosis condition, with 0 being the best and 10 being the worst.
Time frame: From baseline up to Week 52
The study was conducted at one site in Japan from April 2022 to July 2024
| Milestone | Nemolizumab |
|---|---|
| Started | 6 |
| Completed | 6 |
| Not completed | 0 |
Compare pre- and post-treatment total mRSS at Week 24. The investigator assessed the degree of skin thickening for each of 17 sites (fingers of both hands, dorsum of both hands, both forearms, both upper arms, face, anterior chest, abdomen, both thighs, both lower legs, and dorsum of both feet) with a 4-point scale from 0 to 3; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness. The total mRSS is the sum of the mRSS of 17 site
| scores on scale | Nemolizumab |
|---|---|
| Change From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 24 | -9.5 (-13 to -6) |
Compare pre- and post-treatment total mRSS at Week 52. The investigator assessed the degree of skin thickening for each of 17 sites (fingers of both hands, dorsum of both hands, both forearms, both upper arms, face, anterior chest, abdomen, both thighs, both lower legs, and dorsum of both feet) with a 4-point scale from 0 to 3; where 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness. The total mRSS is the sum of the mRSS of 17 site
| scores on scale | Nemolizumab |
|---|---|
| Change From Baseline in Modified Rodnan Total Skin Thickness Score (Total mRSS) at Week 52 | -10.0 (-14 to -7) |
Compare pre- and post-treatment HAQ-DI at Week 24. The HAQ is a questionnaire that patients with chronic diseases answer themselves to assess physical function related to activities of daily living. The questionnaire consists of 20 questions divided into eight categories (dressing and grooming, standing, eating, walking, hygiene, movement, grip strength, and others), which are rated on a four-point scale from 0 to 3. 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. The highest value in each category is the index for that category, and the average of these is the HAQ-DI. The higher the HAQ-DI, the greater the degree of functional impairment.
| scores on scale | Nemolizumab |
|---|---|
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24 | 0.000 (-0.13 to 0.38) |
Compare pre- and post-treatment HAQ-DI at Week 52. The HAQ is a questionnaire that patients with chronic diseases answer themselves to assess physical function related to activities of daily living. The questionnaire consists of 20 questions divided into eight categories (dressing and grooming, standing, eating, walking, hygiene, movement, grip strength, and others), which are rated on a four-point scale from 0 to 3. 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do. The highest value in each category is the index for that category, and the average of these is the HAQ-DI. The higher the HAQ-DI, the greater the degree of functional impairment.
| scores on scale | Nemolizumab |
|---|---|
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 52 | 0.063 (-0.13 to 0.25) |
Compare pre- and post-treatment %FVC at Week 24. %FVC is the ratio of the actual measured FVC to the predicted FVC (predicted based on gender, age, and height).
| percentage of actual to predicted FCV | Nemolizumab |
|---|---|
| Change From Baseline in Percent Forced Vital Capacity (% FVC) at Week 24 | -1.30 (-3.5 to 5.7) |
Compare pre- and post-treatment %FVC at Week 52. %FVC is the ratio of the actual measured FVC to the predicted FVC (predicted based on gender, age, and height).
| percentage of actual to predicted FCV | Nemolizumab |
|---|---|
| Change From Baseline in Percent Forced Vital Capacity (% FVC) at Week 52 | -0.35 (-6.4 to 5.7) |
Compare pre- and post-treatment %DLco at Week 24. Pulmonary diffusion capacity refers to the ability to supply gases such as oxygen from alveoli to the alveolar capillaries. DLco is measured for carbon monoxide (CO) and is expressed as the volume (mL) of CO that transfers from alveolar air to the blood per minute per 1mmHg of alveolar partial pressure. %DLco is the ratio of the actual measured DLco to the predicted DLco (predicated based on age, sex, and height)
| percentage of actual to predicted DLco | Nemolizumab |
|---|---|
| Change From Baseline in Percent Diffusing Capacity of Lung for Carbon Monoxide (%DLco) at Week 24 | 0.55 (-4.5 to 8.8) |
Compare pre- and post-treatment %DLco at Week 52. Pulmonary diffusion capacity refers to the ability to supply gases such as oxygen from alveoli to the alveolar capillaries. DLco is measured for carbon monoxide (CO) and is expressed as the volume (mL) of CO that transfers from alveolar air to the blood per minute per 1mmHg of alveolar partial pressure. %DLco is the ratio of the actual measured DLco to the predicted DLco (predicated based on age, sex, and height)
| percentage of actual to predicted DLco | Nemolizumab |
|---|---|
| Change From Baseline in Percent Diffusing Capacity of Lung for Carbon Monoxide (%DLco) at Week 52 | -3 (-6.6 to 4.4) |
Compare pre- and post-treatment physician's global assessment at Week 24. Physician's global assessment is a visual analogue scale in which the attending physician assess the condition of systemic sclerosis based on severity, damage, and overall disease status. 0 is the best condition and 10 is the worst condition.
| scores on scale | Nemolizumab |
|---|---|
| Change From Baseline in Physician's Global Assessment at Week 24 | -3.30 (-5.4 to -0.9) |
Compare pre- and post-treatment physician's global assessment at Week 52. Physician's global assessment is a visual analogue scale in which the attending physician assess the condition of systemic sclerosis based on severity, damage, and overall disease status. 0 is the best condition and 10 is the worst condition.
| scores on scale | Nemolizumab |
|---|---|
| Change From Baseline in Physician's Global Assessment at Week 52 | -3.10 (-6.5 to -0.6) |
Compare pre- and post-treatment patient's global assessment at Week 24. Patient's Global Assessment is a visual analogue scale in which patients rate their systemic sclerosis condition, with 0 being the best and 10 being the worst.
| scores on scale | Nemolizumab |
|---|---|
| Change From Baseline in Patient's Global Assessment at Week 24 | 1.30 (-1.8 to 3.8) |
Compare pre- and post-treatment patient's global assessment at Week 52. Patient's Global Assessment is a visual analogue scale in which patients rate their systemic sclerosis condition, with 0 being the best and 10 being the worst.
| scores on scale | Nemolizumab |
|---|---|
| Change From Baseline in Patient's Global Assessment at Week 52 | 1.70 (-0.1 to 5.1) |
Collected over From baseline up to Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nemolizumab | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Event | Nemolizumab |
|---|---|
| NasopharyngitisInfections and infestations | 3/6 |
| Adenoviral conjunctivitisInfections and infestations | 1/6 |
| GastroenteritisInfections and infestations | 1/6 |
| ParonychiaInfections and infestations | 1/6 |
| Tinea pedisInfections and infestations | 1/6 |
| Oral herpesInfections and infestations | 1/6 |
| COVID-19Infections and infestations | 1/6 |
| Animal biteInjury, poisoning and procedural complications | 1/6 |
| Ligament sprainInjury, poisoning and procedural complications | 1/6 |
| Vaccination complicationInjury, poisoning and procedural complications | 1/6 |
FAS population included all participants who were enrolled.
| Age, Categorical(Participants) | Nemolizumab |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 5 |
| >=65 years | 1 |
| Age, Continuous(year) | Nemolizumab |
|---|---|
| Median | 53.5 (50 to 66) |
| Sex: Female, Male(Participants) | Nemolizumab |
|---|---|
| Female | 6 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | Nemolizumab |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 0 |
| Unknown or Not Reported | 6 |
| Race (NIH/OMB)(Participants) | Nemolizumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 6 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Nemolizumab |
|---|---|
| Japan | 6 |
| Classification of Primary Disease(Participants) | Nemolizumab |
|---|---|
| Diffuse Cutaneous SSc | 4 |
| Limited Cutaneous SSc | 2 |
| Modified Rodnan Total Skin Thickness Score (Total mRSS)(scores on scale) | Nemolizumab |
|---|---|
| Median | 16 (12 to 22) |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2022 to primary completion in Jun 2024, 25 months.
Results were first posted in Feb 2026, 1 year 8 months after primary completion.
Of 48 phase 2 interventional studies under Scleroderma, Systemic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's 25 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nemolizumab